Table 3.
Influence of selected chemotherapeutic drugs on the expression of EpCAM and LewisY on colorectal tumour cell lines
| HT29 | LoVo | HT29 | LoVo | |
|---|---|---|---|---|
| EpCAM, % | LewisY, % | |||
| Control | 100 | 100 | 100 | 100 |
| 5-fluorouracil | 127 ± 16* | 137 ± 15 | 209 ± 42 | 138 ± 21 |
| Mitomycin-C | 135 ± 19 | 104 ± 13 | 210 ± 20 | 199 ± 43 |
| Oxaliplatin | 129 ± 11 | 114 ± 39 | 230 ± 6 | 176 ± 18 |
| CPT-11 | 98 ± 15 | 104 ± 17 | 98 ± 7 | 106 ± 17 |
| Raltitrexed | 51 ± 17 | 40 ± 16 | 216 ± 20 | 155 ± 27 |
*
Relative percentage of mean fluorescence intensity (MFI) compared with control (without chemotherapeutic drug) demonstrating tumour-associated antigen (TAA) expression of EpCAM and LewisY antigen on the colorectal tumour cell lines HT29 and LoVo after 3 days of incubation with the indicated chemotherapeutic drugs (mean and percent s.d. obtained from five experiments). Indirect immunofluorescence was performed as described in Table 1.
Bold type indicates significant differences of chemotherapeutic drug treatment compared with control.